Use of a systems model of drug-induced liver injury (DILIsym®) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice  by Howell, Brett A. et al.
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Acetaminophen  (APAP)  has  been  used  as  a probe  drug  to investigate  drug-induced  liver injury  (DILI).
In  mice,  3′-hydroxyacetanilide  (AMAP),  a  less-toxic  isomer  of APAP,  has  also  been studied  as  a negative
control.  Various  mechanisms  for the divergence  in  toxicological  response  between  the  two  isomers  have
been  proposed.  This  work  utilized  a mechanistic,  mathematical  model  of DILI to test  the plausibility  of
four  mechanistic  hypotheses.  Simulation  results  were  compared  to  an  array  of measured  endpoints  in
mice  treated  with  APAP  or  AMAP.  The  four hypotheses  included:  (1)  quantitative  differences  in  drug
metabolism  proﬁles  as a result  of different  afﬁnities  for the relevant  enzymes;  (2)  differences  in  the
amount  of reactive  metabolites  produced  due  to cytochrome  P450  (CYP450)  inhibition  by the  AMAP reac-
tive metabolites;  (3)  differences  in  the  rate  of conjugation  between  the  reactive  metabolites  and  proteins;
(4)  differences  in  the  downstream  effects  or potencies  of the  reactive  metabolites  on  vital  components
within  hepatocytes.  The simulations  did  not support  hypotheses  3  or 4 as  the  most  likely  hypotheses
underlying  the  difference  in  hepatoxic  potential  of  APAP  and  AMAP.  Rather,  the  simulations  supportedeactive metabolite
ice
imulation
aracetamol
hypotheses  1 and  2 (less  reactive  metabolite  produced  per  mole  of AMAP  relative  to  APAP).  Within  the
simulations,  the  difference  in  reactive  metabolite  formation  was  equally  likely  to  have  occurred  from
differential  afﬁnities  for the relevant  drug  metabolism  enzymes  or from  direct  CYP450  inhibition  by the
AMAP  reactive  metabolite.  The  demonstrated  method  of using  simulation  tools  to  probe  the  importance
of  possible  contributors  to toxicological  observations  is generally  applicable  across  species.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  Open access under CC BY-NC-ND license.. Introduction
Drug induced liver injury (DILI) is a signiﬁcant healthcare prob-
em (Bleibel et al., 2007; Corsini et al., 2012; Hayashi and Watkins,
009; Kaplowitz and DeLeve, 2013; Lee, 2003; Watkins, 2005). This
s true for clinicians and patients, as many cases of liver injury,
cute liver failure, liver transplant, and death are caused each year
orldwide from DILI (Larson et al., 2005; Lee, 2008, 2003). DILI is
qually problematic for drug developers, who commonly abandon
romising drugs in the midst of development due to unexpected
igns of liver injury, or worse, have drugs removed from the mar-
et after a few patients experience, rare, idiosyncratic DILI (Senior,
007; Watkins, 2011). In an effort to resolve these issues, many
esearchers have studied DILI with the goal of identifying key
∗ Corresponding author. Tel.: +1 919 558 1323.
E-mail addresses: bhowell@thehamner.org, bretthowell 28023@yahoo.com
B.A. Howell).
ttp://dx.doi.org/10.1016/j.toxlet.2014.02.007
378-4274/© 2014 The Authors. Published by Elsevier Ireland Ltd. Openattributes of DILI-causing agents. No exemplar hepatotoxicant has
been studied more often or more thoroughly than acetaminophen
(APAP). As the dominant cause of DILI cases seen clinically, includ-
ing liver failure (Lee, 2008), APAP is an important drug to study for
obvious reasons. APAP is also used as a probe drug to understand
mechanistic linch-pins in the DILI process. This is commonly done
in mice, which show a greater sensitivity to APAP-induced liver
injury than rats (McGill et al., 2012).
In the midst of studying APAP in mice, an analogue of APAP,
3′-hydroxyacetanilide (AMAP), has been utilized as a comparator
to APAP due to its apparent lack of liver toxicity in mice. AMAP
was originally patented as a possible alternative to APAP (Nelson,
1980a). While it appears to be non-toxic in mice, AMAP has been
examined in human and rat liver slices, and shown to poten-
tially be more toxic in these species (Hadi et al., 2012). Over the
past 30 years, many hypotheses describing the mechanistic under-
pinnings of the divergence in liver toxicity seen between APAP
and AMAP in mice have been proposed by various researchers.
However, one could argue that deﬁnitive conclusions have not
 access under CC BY-NC-ND license.
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et been reached. The goal of this work was to employ a mech-
nistic, mathematical model of DILI (DILIsym® v1A) to test the
lausibility of several of these hypotheses. The DILIsym® model
llowed for comparisons between simulation results based on dif-
erent hypotheses and published results on APAP/AMAP responses
ithin a quantitative, mechanistically focused framework. While
his investigation focused entirely on APAP and AMAP in mice, it
epresents a generally applicable approach that can be applied else-
here in toxicology, including to human DILI events. In addition,
ILIsym® can be applied to cross-species hepatotoxicity investi-
ations, where the focus is understanding why different species
espond differently to the same drug (Howell et al., 2012).
A wide variety of studies on APAP versus AMAP have been con-
ucted. Many have focused on the in vivo metabolism of one or both
f the molecules (Dai et al., 2006; Hamilton and Kissinger, 1986;
ee et al., 2009; McGill et al., 2013; Rashed et al., 1990; Vaccarino
t al., 2007). Others have taken an in vitro approach to under-
tanding metabolism and potency differences using microsomes
r hepatocytes (Bauman et al., 2009; Holme et al., 1991; Rashed
t al., 1989; Streeter et al., 1984). Covalent binding studies have
lso been a prevailing theme (Rashed et al., 1990; Roberts et al.,
990). In vivo toxicity endpoints, such as glutathione (GSH) and
iver injury biomarkers, have commonly been measured (Nelson,
980b; Priyadarsiny et al., 2008; Salminen et al., 1997; Tirmenstein
nd Nelson, 1989). Mechanistic investigations have also focused
n drug metabolism, where enzyme inhibition studies have shown
MAP to inhibit its own reactive metabolite production (Halmes
t al., 1998). More recently, investigations of downstream per-
urbations of liver homeostasis, such as gene expression and
ritical pathway analysis, have been done (Priyadarsiny et al.,
008; Salminen et al., 1997; Stamper et al., 2010). The totality
f the literature was reviewed for distinct mechanistic hypothe-
es that could explain the divergence in toxicological response
etween APAP and AMAP. The various reports were narrowed to
our primary hypotheses that offered explanations for the observed
ifferences. Of the various hypotheses listed above, the four below
ere deemed most supported by published data and most compre-
ensive:
Hypothesis 1 – the structure of AMAP lends itself to a quanti-
tatively different drug metabolism proﬁle than APAP (and less
reactive metabolite produced as a result);
Hypothesis 2 – the default metabolism parameters describing the
conversion from parent compound to glucuronide, sulfate, and
reactive metabolite conjugates are the same for APAP and AMAP,
but the AMAP reactive metabolite inhibits its own  production
through mechanism-based inhibition of CYP2E1;
Hypothesis 3 – the AMAP reactive metabolite binds to cellular
proteins at a higher rate than the APAP reactive metabolite (and
thus depletes less GSH);
Hypothesis 4 – AMAP reactive metabolites cause injury or dis-
rupt cellular processes in different (and less potent) ways on an
equimolar basis than APAP reactive metabolites.
Hypotheses 1 and 2 can be viewed as ‘upstream’ or drug
etabolism hypotheses, while Hypotheses 3 and 4 relate more to
he action or properties of the reactive metabolites generated by
PAP and AMAP.
. Materials and methods
A mechanistic, mathematical model of drug-induced liver injury was  the pri-
ary  means used to accomplish the goal of this work: elucidating the most
ikely mechanistic explanation for why APAP and AMAP show divergent toxico-
ogical responses in mice. Accordingly, some general information about the model
DILIsym® v1A) is discussed below. The general process of simulating exposure to
PAP and AMAP in mice is summarized. Next, the four hypotheses tested with thetters 226 (2014) 163–172
model in the baseline mouse are described in detail, including which parameters in
the  model were adjusted to simulate each scenario.
2.1. The DILIsym® model, version 1A
The DILI-sim Initiative is a joint effort between the Hamner Institutes for
Health Sciences and the pharmaceutical industry. The goals of the DILI-sim Initia-
tive include developing DILIsym® , a predictive, mechanistic, mathematical model of
drug induced liver injury (DILI), and advancing the knowledge of DILI for all parties
involved (see www.DILIsym.com for more information on the goals and scope of
DILI-sim). The method for model design is best described as ‘middle out.’ The ‘mid-
dle  out’ approach involves starting at the organ level (liver in this case), and working
down to the molecular level or up to the organism level when necessary (Michelson
et  al., 2006; Shoda et al., 2010). As a result, this is a multi-scale approach, where
models based on different scales are connected through scaling factors. The model
is  organized into various smaller sub-models, but all sub-models are mathematically
integrated to simulate an organism level response. DILIsym® version 1A primarily
focuses on C57Bl6 mice, Sprague Dawley rats, and humans (the mouse representa-
tion  was used for this analysis). Exemplar hepatotoxic compounds were sequentially
used to add mechanistic detail to the model. APAP was the ﬁrst exemplar repre-
sented. DILIsym® v1A is therefore primarily a model of oxidative stress-induced
hepatotoxicity.
Since the necessary drug absorption, distribution, metabolism, and excretion
(ADME) sub-model frameworks were built within version 1A using APAP, this anal-
ysis of APAP versus AMAP was a natural extension of previous work. Additional
DILI mechanisms have since been and are currently being added to future versions
of  the model. More information on DILIsym® version 1A is available through sev-
eral previously published articles (Bhattacharya et al., 2012; Howell et al., 2012;
Shoda et al., 2014; Woodhead et al., 2012). These articles include a more thorough
description of the DILIsym® sub-models, data samples used for model optimization,
and  a comprehensive list of the data used for version 1A. The model is also directly
available to industry through membership in the DILI-sim Initiative. Academic and
non-proﬁt groups may  access the model by contacting the Hamner Institutes for
Health Sciences or the corresponding author.
2.1.1. Comparing AMAP to APAP in mice in DILIsym®
The underlying assumption of the present work is that DILIsym® v1A ade-
quately simulates a hepatotoxic event in mice arising from APAP exposure. The
methods used to construct the model were discussed in several previous publica-
tions (Bhattacharya et al., 2012; Howell et al., 2012; Shoda et al., 2014; Woodhead
et  al., 2012). To brieﬂy summarize the series of assumptions leading to APAP toxic-
ity  simulation in DILIsym® v1A, the inputs include the desired dosing quantity and
route. With regard to this study, the simulated quantities of APAP and AMAP dosed,
as  well as the routes, were taken from the cited publications used for the compari-
son. Once the simulation is initiated, DILIsym® v1A accounts for the absorption and
distribution of the drug. APAP (or AMAP) is then converted via one of three metabolic
pathways: sulfation, glucuronidation, or CYP-mediated reactive metabolite produc-
tion. The sulfate and glucuronide metabolites are represented as inert with regard
to  liver toxicity. The reactive metabolite is conjugated in two possible ways. GSH
conjugation is represented with an extremely high reaction rate, but is only avail-
able in limited quantities (substrate limited). Protein adduction is also represented.
Protein availability is not assumed to be a constraint, but the rate of reaction for
reactive metabolite/protein conjugation is much lower than for GSH  conjugation,
based on published data used to optimize the rate constant (Howell et al., 2012;
Woodhead et al., 2012). Once GSH depletion occurs, the reactive metabolite can
build up in the representative liver tissue compartments until GSH recovery occurs
or  protein adduction occurs. The reactive metabolite concentration in the liver is the
actual perpetrator of toxicity in DILIsym® v1A. A function connects the concentration
of  reactive metabolite in the liver to oxidative stress generation, which is subse-
quently connected to ATP production. As reactive metabolite accumulates, oxidative
stress accumulates, ATP production and concentration decline, and necrosis ensues.
Details on the equation structure and parameters dictating these processes are avail-
able in previously published articles (Bhattacharya et al., 2012; Howell et al., 2012;
Woodhead et al., 2012) or in DILIsym® version 1A, which can be accessed as directed
above. The level of mechanistic detail included in v1A is important to understand
when considering each of the four hypotheses discussed below. For each hypothe-
sis,  any limitations or assumptions that could inﬂuence conclusions regarding APAP
versus AMAP are pointed out.
To utilize DILIsym® v1A to identify the most likely mechanistic rationale for
divergent toxicological responses for APAP versus AMAP in mice, the baseline APAP
model for mice was ﬁrst used. Baseline mice in the model represent ‘average’ or
‘mean’ responses when compared to a larger group of mice. For the purposes of this
work, the APAP model in mouse was considered to be the starting point. Exper-
imental protocols where APAP was administered to mice were initially simulated
(Priyadarsiny et al., 2008; Rashed et al., 1990; Salminen et al., 1997; Tirmenstein and
Nelson, 1989). Changes were then made to parameter values within the model in a
step-wise fashion to mimic hypothesized mechanistic differences between APAP
and AMAP hepatotoxicity (Hypotheses 1–4), and experimental protocols where
AMAP was  dosed to mice were also simulated (Priyadarsiny et al., 2008; Rashed
et  al., 1990; Salminen et al., 1997; Tirmenstein and Nelson, 1989). While the entirety
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f the steps and complexities involved in the hypotheses were not included (i.e. sim-
liﬁcations were made), we believe the broad hypotheses tested remain consistent
ith the design and parameterization of the mathematical framework. Underly-
ng  the parameter value changes in a step-wise fashion is a key assumption: all
ther processes and modelling assumptions for APAP, besides the speciﬁc changes
mplemented, were assumed to be exactly the same between the two molecules.
he possibility that more than one mechanistic difference exists between the two
olecules cannot be ruled out. As such, the reader should consider this approach as
 method for determining which process is likely to be the dominant reason for the
ivergence in response. Note that simulation results for isolated hypothetical mech-
nisms are capable of suggesting that no single mechanism is sufﬁcient to account
or  the divergent response. The methods for implementing the four hypotheses
imulated herein are outlined below.
.1.2. Hypothesis 1 – metabolic partitioning is different
Hypothesis 1 basically assumes that both APAP and AMAP produce a reac-
ive  metabolite that could lead to oxidative stress in hepatocytes, which results
n  ATP loss and cell death, but less reactive metabolite is produced from AMAP
han APAP. This hypothesis was based on the cumulative APAP and AMAP recov-
ry  data in mice reported by Rashed et al. (1990). They observed signiﬁcantly more
lucuronidated AMAP species than APAP, and signiﬁcantly less reactive metabolite
pecies for AMAP compared to APAP. Thus, the three maximum velocity parame-
er  values that control the amount of APAP converted to sulfate, glucuronide, and
-acetyl-p-benzoquinone imine (NAPQI, which is the APAP reactive metabolite)
onjugates were adjusted to match the 24 h cumulative AMAP proﬁle from Rashed
t  al. (1990). Table 1 shows the parameters that were adjusted.
The non-reactive metabolite pathways were increased and the reactive metabo-
ite  pathway was decreased. Under this assumption, the reactive metabolites were
ssumed to cause the same amount of oxidative stress per mole. Therefore, of critical
mportance for this assumption was the existence of the model of mouse response
o  APAP, which had been calibrated to produce the correct amount of simulated
xidative stress per mole of NAPQI produced.
.1.3. Hypothesis 2 – AMAP reactive metabolite inhibits CYP2E1
Hypothesis 2 is similar to Hypothesis 1 in that it focuses solely on the amount
f  reactive metabolite produced. Underlying Hypothesis 2 is the assumption that
he  drug metabolism parameters describing the conversion rates from parent com-
ound to glucuronide, sulfate, and reactive metabolite conjugates are the same for
PAP and AMAP, but that the AMAP reactive metabolite inhibits its own production
hrough mechanism-based inhibition (covalent binding) of CYP2E1. CYP inhibition
or  the AMAP reactive metabolite was initially reported by Halmes et al. (1998). This
nhibition was  simulated by reducing the maximum velocity parameter for the pro-
uction of NAPQI from AMAP by 75%, consistent with reported rates (Halmes et al.,
998). Reactive metabolite production rates decreased, although the sulfate and
lucuronide pathways were not altered. An important distinction between Hypoth-
sis 1 and 2 involves the methods for arriving at the parameter value alterations.
or  Hypothesis 1, the three parameters mentioned above were ‘tuned’ to the 24 h
umulative metabolite proﬁle reported by Rashed et al. For Hypothesis 2, the maxi-
um  velocity for reactive metabolite production was multiplied by ‘0.25’ to simulate
5% inhibition. No comparisons to the cumulative metabolite proﬁles were done
o  choose this level of inhibition. Rather, it was based solely on the level of inhi-
ition reported in the literature. Halmes et al. reported inhibition levels consistent
ith a 75% reduction in the maximum velocity parameter. For exploratory purposes,
ther levels of inhibition were also simulated and the results are discussed brieﬂy
n  Section 4.
.1.4. Hypothesis 3 – AMAP reactive metabolite is more reactive than NAPQI
Unlike Hypotheses 1 and 2, Hypothesis 3 hinges on the reactive metabolites from
PAP and AMAP interacting with hepatocytes differently. Speciﬁcally, Hypothesis
 suggests that the AMAP reactive metabolite covalently binds to cellular proteins
t  a higher rate than NAPQI. This has been suggested by several authors previously
Rashed et al., 1990; Roberts et al., 1990; Salminen et al., 1997; Streeter et al., 1984).
espite observations of similar levels of protein adducts for APAP and AMAP in
ouse livers (Rashed et al., 1990), the rate of protein binding to the AMAP reactive
etabolite was  still likely higher due to less total reactive metabolite produced for
MAP (and a resulting lower reactive metabolite to protein adduct ratio). Higher
eactive metabolite reactivity could lead to lower toxicity for AMAP in at least two
ays. First, more AMAP binding to proteins could result in less AMAP binding to
lutathione (GSH), which could prevent GSH from reaching critically low levels. In
his scenario, covalent binding is acting as an elimination pathway for the reactive
etabolite. To simulate this hypothesis, the rate constant that speciﬁes the ﬁrst-
rder reaction rate between reactive metabolite and proteins was  increased by over
wo fold. Thus, the primary question addressed was: could higher AMAP reactive
etabolite binding act as a quantitatively signiﬁcant clearance route for the reactive
etabolite? A 1:1 stoichiometry was assumed for the simulations (one molecule ofeactive metabolite binds to one protein).
On the other hand, Hypothesis 3 could also be interpreted differently. Many
esearchers have proposed that higher reactivity with proteins could cause the
MAP reactive metabolite to selectively bind to proteins near the site of reactive
etabolite generation, while the APAP reactive metabolite (NAPQI) may  be moretters 226 (2014) 163–172 165
capable of diffusing to critical sites, such as mitochondria, and binding to more crit-
ical  proteins (Birge et al., 1989; Holme et al., 1991; Rashed et al., 1990; Roberts et al.,
1990; Streeter et al., 1984; Tirmenstein and Nelson, 1989). DILIsym® v1A does not
include speciﬁc proteins bound by reactive metabolites and the functions associated
with each of those proteins. As a result, this component of Hypothesis 3 cannot be
directly simulated with the DILIsym® model. An opinion and analysis of selective
protein binding and its potential effect on toxicity is addressed in Section 4, despite
the inability to directly simulate this hypothesis.
2.1.5. Hypothesis 4 – downstream damage pathway processes drive the
divergence
The  fourth and ﬁnal hypothesis assumes that reactive metabolites are causing
injury or disrupting cellular processes in different ways on an equimolar basis. Sev-
eral researchers have examined the downstream differences in toxicity for AMAP
versus APAP (Priyadarsiny et al., 2008; Salminen et al., 1997; Stamper et al., 2010).
All  have shown differences in pathways, proteins, or genes affected by APAP com-
pared to AMAP. Still, one important question regarding these studies remains: are
the resulting differences a consequence of upstream metabolic factors driving diver-
gent toxic responses, or are the differences causing the divergence seen (cause or
effect)? Hypothesis 4 assumes they are the cause of the divergence, and provides
the opportunity to test this theory and compare the available data to simulations
under this assumption.
To implement Hypothesis 4, all parameter values within DILIsym® v1A for APAP
in  mice were assumed to be the same for AMAP except the parameter connecting
the  concentration of reactive metabolite in the liver to oxidative stress production in
the  liver. Many details surrounding the events of oxidative stress induction remain
unclear (Burke et al., 2010; Hinson et al., 2010), and this process is therefore sim-
pliﬁed and empirically modelled in DILIsym® v1A. A change in the parameter value
governing this process acts as a surrogate for a whole host of potential injury path-
way divergences, including gene regulation. This parameter was  reduced by 67%
to  give a similar level of liver injury for AMAP as observed in published reports
(Priyadarsiny et al., 2008; Tirmenstein and Nelson, 1989). This is analogous to how
Hypothesis 1 was  tested, except that Hypothesis 1 involved ‘tuning’ the model to
the  correct cumulative drug metabolism pathway outputs, whereas Hypothesis 4
involved ‘tuning’ the model to the correct liver injury outputs.
2.1.6. Endpoints for comparison between APAP and AMAP
For each of the four hypotheses described above, a different modiﬁcation to
DILIsym® v1A parameter values was implemented to represent AMAP instead of
APAP. The resulting simulations were compared to the AMAP data and APAP simu-
lations and data to determine how well simulated toxicological responses between
APAP and AMAP mimicked the differential responses observed in the published
studies. Three primary mouse data sets were used: cumulative urinary parent and
metabolite accumulation (Rashed et al., 1990), minimum GSH levels observed dur-
ing in vivo studies (Rashed et al., 1990; Salminen et al., 1997), and maximum ALT
values observed (Priyadarsiny et al., 2008; Tirmenstein and Nelson, 1989). ALT was
an appropriate primary endpoint for acetaminophen hepatotoxicity due to a previ-
ously demonstrated correlation between histologic assessment of liver necrosis and
serum ALT (Harrill et al., 2009). For each of these data components, the important
consideration for this study was  how the reported response differed between APAP
and AMAP, and correspondingly, how the response differed from simulated APAP to
simulated AMAP. To elucidate the mechanistic differences in toxicity between the
compounds, the relative change from one compound to the other was  more crit-
ical than the absolute response for one compound compared to the data for that
compound. The ﬁgures and text in Section 3 show the data and simulation results
for  both compounds for all four hypotheses tested. Note that the APAP/AMAP data
and  APAP simulation results are the same across all the ﬁgures, as only the AMAP
parameter representations were adjusted for each hypothesis.
3. Results
3.1. Hypothesis 1 testing in the baseline mouse – metabolic
partitioning is different
The simulated and reported cumulative parent and metabolites
recovered for AMAP (Hypothesis 1) are shown in Fig. 1A. The sim-
ulated APAP values are also shown alongside the AMAP data.
Note that the APAP data shown was  not used to optimize
DILIsym® v1A and the APAP simulations agree with the APAP data,
providing validation that the APAP model is a reasonable predictor
of APAP metabolism in mice. The APAP predictions of minimum
GSH (Fig. 1B) and maximum ALT (Fig. 2) are also in line with
the data, particularly when considering between-study variability.
Most importantly, the simulations and data qualitatively agree for
APAP: signiﬁcant liver injury occurred.
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Table 1
Parameters describing the metabolism of N-acetyl-meta-aminophenol (AMAP) versus acetaminophen (APAP) in mice used for Hypothesis 1 testing.
Parameter name Parameter in DILIsym® v1A APAP AMAP Fold change (AMAP
relative to APAP)
Vmax – CYP450 reactive metabolite formationa (mol/h/kg0.75) Vmax NAPQI 2.74e−4b 6.85e−5c 0.25
Vmax – glucuronidation (mol/h/kg0.75) Vmax gluc 8.4e−3b 1.09e−2c 1.3
Vmax – sulfation (mol/h/kg0.75) Vmax sulf 8.53e−5b 1.28e−4c 1.5
a Once APAP or AMAP is converted to their respective reactive metabolites, the DILIsym® model allows for covalent binding to glutathione and/or proteins (to form protein
adducts). The ﬁrst order reaction rates for the reactive metabolite/protein reactions were estimated using covalent binding data from several sources as explained and cited
in  Howell et al. (2012).
b Values ﬁrst published in Howell et al. (2012).
c Vmax values were adjusted for AMAP based on cumulative APAP and AMAP metabolism studies in Rashed et al. (1990).
Fig. 1. Comparisons of data and simulations across APAP and AMAP for the mechanistic hypothesis of different metabolic partitioning (Hypothesis 1). (A) Cumulative
metabolite and parent elimination at 24 h after 250 mg/kg APAP and 600 mg/kg AMAP in mice (normalized to total amount recovered). Solid bars show data measured in
Rashed et al. (1990). Dark grey bars represent APAP and white bars represent AMAP. Striped bars show corresponding simulated proﬁles from DILIsym® v1A. Dark bars with
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PAP  and AMAP, including measurements and simulations. Doses of APAP and AMA
000  mg/kg (Salminen et al., 1997). All simulations and measurements are for mice
The observed increase in glucuronidation and decrease in reac-
ive metabolite generation (relative to APAP) are captured in the
imulated AMAP results. This is no surprise, as Hypothesis 1
nvolved ‘tuning’ the model to match the AMAP data shown in
ig. 1A (Table 1). The key ﬁgures to review for Hypothesis 1 are
ig. 2. Comparisons of data and simulations across APAP and AMAP for the mech-
nistic hypothesis of different metabolic partitioning (Hypothesis 1). Comparison
f maximum observed or simulated alanine transaminase (ALT) in serum for APAP
nd AMAP, including measurements and simulations. Solid bars show data while
triped bars show corresponding simulated proﬁles from DILIsym® v1A. Dark grey
ars  represent APAP and white bars represent AMAP. Dark bars with white stripes
epresent APAP and white bars with dark stripes represent AMAP. Doses of APAP
nd AMAP, respectively, were 250 mg/kg and 600 mg/kg (Tirmenstein and Nelson,
989), and 400 mg/kg and 400 mg/kg (Priyadarsiny et al., 2008). All simulations and
easurements are for mice.parison of minimum glutathione (GSH) in the liver as a percentage of baseline for
pectively, were 250 mg/kg and 600 mg/kg (Rashed et al., 1990), and 200 mg/kg and
Figs. 1B and 2. Fig. 1B demonstrates that the higher minimum GSH
observed for AMAP was accurately predicted. Fig. 2 illustrates how
the model agreed with the AMAP data with regard to minimal liver
injury. Hypothesis 1 led to simulation results that agreed well with
measured values for AMAP.
3.2. Hypothesis 2 testing in the baseline mouse – AMAP reactive
metabolite inhibits CYP2E1
When implementing a parameter change to mimic 75% CYP2E1
inhibition by the AMAP reactive metabolite (Hypothesis 2), the
reduced level of reactive metabolite production for AMAP was  sim-
ilar to levels observed in literature (Fig. 3A).
As a result of the smaller reactive metabolite pathway ﬂux,
the glucuronidation ﬂux was also increased, despite the parameter
value for glucuronidation being equal to the value for APAP (Fig. 3A).
Corresponding predictions of minimum GSH in Fig. 3B show the
correct increasing trend for AMAP compared to APAP, although the
simulations are not as quantitatively in agreement for AMAP GSH
compared to Hypothesis 1. Regardless, the liver injury predicted for
AMAP under Hypothesis 2, indicated by ALT in Fig. 4, was minimal
compared to APAP. Hypothesis 2 also led to simulation results that
generally agreed well with measured values for AMAP.
3.3. Hypothesis 3 testing in the baseline mouse – AMAP reactive
metabolite is more reactive than NAPQIHypothesis 3 tested the idea that an increased reactivity
between AMAP reactive metabolites and proteins could account
for the observed differences. The simulated increase in the rate of
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Fig. 3. Comparisons of data and simulations across APAP and AMAP for the mechanistic hypothesis of self-inhibition of CYP2E1 (75%) by the AMAP reactive metabolite
(Hypothesis 2). (A) Cumulative metabolite and parent elimination at 24 h after 250 mg/kg APAP and 600 mg/kg AMAP in mice (normalized to total amount recovered). Solid
bars  show data measured in Rashed et al. (1990). Dark grey bars represent APAP and whi
DILIsym® v1A. Dark bars with white stripes represent APAP and white bars with dark st
as  a percentage of baseline for APAP and AMAP, including measurements and simulation
et  al., 1990), and 200 mg/kg and 1000 mg/kg (Salminen et al., 1997). All simulations and m
Fig. 4. Comparisons of data and simulations across APAP and AMAP for the mecha-
nistic hypothesis of self-inhibition of CYP2E1 (75%) by the AMAP reactive metabolite
(Hypothesis 2). Comparison of maximum observed or simulated alanine transami-
nase (ALT) in serum for APAP and AMAP, including measurements and simulations.
Solid bars show data while striped bars show corresponding simulated proﬁles from
DILIsym® v1A. Dark grey bars represent APAP and white bars represent AMAP. Dark
bars  with white stripes represent APAP and white bars with dark stripes repre-
sent AMAP. Doses of APAP and AMAP, respectively, were 250 mg/kg and 600 mg/kg
(Tirmenstein and Nelson, 1989), and 400 mg/kg and 400 mg/kg (Priyadarsiny et al.,
2008). All simulations and measurements are for mice.
Fig. 5. Comparisons of data and simulations across APAP and AMAP for the mechanis
(Hypothesis 3). (A) Cumulative metabolite and parent elimination at 24 h after 250 mg/kg
bars  show data measured in Rashed et al. (1990). Dark grey bars represent APAP and whi
DILIsym® v1A. Dark bars with white stripes represent APAP and white bars with dark st
as  a percentage of baseline for APAP and AMAP, including measurements and simulation
et  al., 1990), and 200 mg/kg and 1000 mg/kg (Salminen et al., 1997). All simulations and m
are  not visible due to the very low minimum GSH concentration predicted from Hypothete bars represent AMAP. Striped bars show corresponding simulated proﬁles from
ripes represent AMAP. (B) Comparison of minimum glutathione (GSH) in the liver
s. Doses of APAP and AMAP, respectively, were 250 mg/kg and 600 mg/kg (Rashed
easurements are for mice.
protein adduction did not shift the metabolism of AMAP towards
glucuronidation as the data suggests (Fig. 5A), nor did it result in
less reactive metabolite generation (Fig. 5A).
Even still, the additional elimination of reactive metabolite
could theoretically lead to less GSH depletion, less oxidative stress,
and therefore less injury. Fig. 5B is evidence to the contrary. GSH
stores were completely exhausted under this scenario for AMAP.
Furthermore, Fig. 6 provides ALT comparisons that suggest injury
from AMAP was predicted to be as signiﬁcant or worse as compared
to APAP under this hypothesis.
To help address the question of why  a shift towards protein
binding did not lead to a simulated decrease in GSH depletion and
less liver injury, Fig. 7 was assembled.
Fig. 7 compares the total reactive metabolite products measured
and simulated for both compounds with the total protein adducts
measured at 24 h in the liver for both compounds. Note that the
data for protein adducts were reported in normalized units, and
conversions were done to produce protein adduct estimates per
whole liver (Brown et al., 1997). The important aspect of Fig. 7 is
the magnitude of protein adducts detected compared to the total
reactive metabolite mass. In short, the amount of protein adducts is
several orders of magnitude lower than the total reactive metabo-
lite mass, making the magnitude of protein binding insigniﬁcant
tic hypothesis of the AMAP reactive metabolite being more reactive than NAPQI
 APAP and 600 mg/kg AMAP in mice (normalized to total amount recovered). Solid
te bars represent AMAP. Striped bars show corresponding simulated proﬁles from
ripes represent AMAP. (B) Comparison of minimum glutathione (GSH) in the liver
s. Doses of APAP and AMAP, respectively, were 250 mg/kg and 600 mg/kg (Rashed
easurements are for mice. Note that the minimum simulated GSH bars for AMAP
sis 3.
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Fig. 6. Comparisons of data and simulations across APAP and AMAP for the mecha-
nistic hypothesis of the AMAP reactive metabolite being more reactive than NAPQI
(Hypothesis 3). Comparison of maximum observed or simulated alanine transami-
nase (ALT) in serum for APAP and AMAP, including measurements and simulations.
Solid bars show data while striped bars show corresponding simulated proﬁles from
DILIsym® v1A. Dark grey bars represent APAP and white bars represent AMAP. Dark
bars with white stripes represent APAP and white bars with dark stripes repre-
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Fig. 8. Comparisons of data and simulations across APAP and AMAP for the mech-
anistic hypothesis of downstream damage processes differing between the AMAP
reactive metabolite and NAPQI (Hypothesis 4). Comparison of maximum observed
or  simulated alanine transaminase (ALT) in serum for APAP and AMAP, including
measurements and simulations. Solid bars show data while striped bars show cor-
responding simulated proﬁles from DILIsym® v1A. Dark grey bars represent APAP
and white bars represent AMAP. Dark bars with white stripes represent APAP and
white bars with dark stripes represent AMAP. Doses of APAP and AMAP, respectively,ent AMAP. Doses of APAP and AMAP, respectively, were 250 mg/kg and 600 mg/kg
Tirmenstein and Nelson, 1989), and 400 mg/kg and 400 mg/kg (Priyadarsiny et al.,
008). All simulations and measurements are for mice.
nless levels are simulated beyond the range of the measured data.
o further make this point, the reactive metabolite pathway prod-
ct mass is probably best reported in micromoles, while the protein
dduct concentrations are customarily reported in nanomoles.
.4. Hypothesis 4 testing in the baseline mouse – downstream
amage pathway processes drive the divergence
Adjusting the DILIsym® v1A parameter connecting reactive
etabolite concentrations in the liver to oxidative stress produc-
ion for APAP in mice resulted in a reduced level of liver injury for
MAP, which is indicated in Fig. 8.
ig. 7. Comparisons of data and simulations across APAP and AMAP for the amount
f reactive metabolite recovered over 24 h and the amount of covalently bound pro-
ein adducts in the liver at 24 h. The mechanistic hypothesis of different metabolic
artitioning (Hypothesis 1) was used to generate the simulation results. Solid bars
how data while striped bars show corresponding simulated proﬁles from DILIsym®
1A. Dark grey bars represent APAP and white bars represent AMAP. Dark bars with
hite stripes represent APAP and white bars with dark stripes represent AMAP.
oses of APAP and AMAP, respectively, were 250 mg/kg and 600 mg/kg (Rashed
t  al., 1990). All simulations and measurements are for mice. The data reported in
ashed et al. (1990) were adapted based on an estimated total body weight and liver
eight for mice to reach total mass recovered, rather than fractions of the total dose
s  reported in the paper. Note that the protein adduct bars are not visible due to
he  magnitude of the values compared to the magnitude of the reactive metabolites
ecovered.were 250 mg/kg and 600 mg/kg (Tirmenstein and Nelson, 1989), and 400 mg/kg and
400 mg/kg (Priyadarsiny et al., 2008). All simulations and measurements are for
mice.
This is again no surprise, as Hypothesis 4 involved ‘tuning’ the
model to get a similar level of liver injury as seen in the AMAP
studies. Fig. 9 addresses the validity of this hypothesis when consid-
ering all the reported metrics simultaneously. Fig. 9A shows clear
disagreement between the AMAP data and simulations. Likewise,
simulated GSH stores were completely depleted (Fig. 9B). Hypoth-
esis 4 led to reasonable concurrence between the simulations and
data for liver injury, but not for drug metabolism or GSH deple-
tion.
4. Discussion
One of the many advantages of utilizing mechanistic, mathemat-
ical representations of complex processes is piece-wise hypothesis
testing aimed at elucidating important but non-obvious conclu-
sions. This method has been utilized in numerous cases to shed
light on difﬁcult problems (Gandelman et al., 2010; Geenen et al.,
2012; Howell and Chauhan, 2010; Johnson et al., 2010; Lam and
Hunt, 2009; Punt et al., 2009; Woodhead et al., 2012). Simulations
of hypotheses on why  AMAP toxicity in mice is reduced com-
pared to APAP suggests that two of the four hypotheses tested are
more plausible than the other two. Table 2 provides a summary
of agreement between simulations and data for each hypothe-
sis. The absolute value of the difference between the measured
and simulated endpoints is also shown in Table 2 for each end-
point/hypothesis combination. In cases where the endpoints were
measured and simulated for two studies (GSH and ALT), the dif-
ferences were averaged. The differences quantitatively illustrate
that Hypotheses 1 and 2 were suggested as most plausible by the
simulations.
4.1. Quantity of reactive metabolite produced appears most
plausible
Hypotheses 1 and 2 assume that each mole of reactive metabo-
lite generated from APAP initiates oxidative stress identically to a
mole of reactive metabolite generated from AMAP, but less reac-
tive metabolite is produced for the latter case. Both led to simulated
cumulative drug metabolism proﬁles that included three-fold less
reactive metabolite from AMAP, which agreed with the published
data. Likewise, both Hypotheses 1 and 2 led to GSH depletion and
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Fig. 9. Comparisons of data and simulations across APAP and AMAP for the mechanistic hypothesis of downstream damage processes differing between the AMAP reactive
metabolite and NAPQI (Hypothesis 4). A) Cumulative metabolite and parent elimination at 24 h after 250 mg/kg APAP and 600 mg/kg AMAP in mice (normalized to total
amount recovered). Solid bars show data measured in Rashed et al. (1990). Dark grey bars represent APAP and white bars represent AMAP. Striped bars show corresponding
simulated proﬁles from DILIsym® v1A. Dark bars with white stripes represent APAP and white bars with dark stripes represent AMAP. (B) Comparison of minimum glutathione
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SH  bars for AMAP are not visible due to the very low minimum GSH concentration
LT elevation results consistent with published reports. However,
he question of whether less AMAP reactive metabolite is pro-
uced due to different afﬁnities for the relevant CYP’s (Hypothesis
) versus direct CYP2E1 inhibition (Hypothesis 2) is not directly
ddressable with DILIsym® v1A. Both are equally supported by the
imulations.
able 2
ummary of agreement between measured data and DILIsym® v1A simulation results for
imulate  the differences in observed toxic potencies between AMAP and APAP.
Rashed et al. (1990).
Rashed et al. (1990) and Salminen et al. (1997).
Priyadarsiny et al. (2008) and Tirmenstein and Nelson (1989).
Simulation results and measured data agree.
Simulation results and measured data do not agree.
The absolute value of the difference between the measured endpoint and the simulated e
n  cases where the endpoints were measured and simulated for two  studies (GSH and ALnts and simulations. Doses of APAP and AMAP, respectively, were 250 mg/kg and
ll simulations and measurements are for mice. Note that the minimum simulated
icted from Hypothesis 4.
Hypothesis 3 focused on the reactivity of the AMAP reactive
metabolite. Simulations of increased reactivity between the AMAP
reactive metabolite and non-speciﬁc proteins did not show pro-
tection from GSH depletion and decreased injury in the simulated
mouse. Fig. 7 illustrates why: the amount of covalent adducts simu-
lated (and measured) during APAP/AMAP dosing to mice (and other
 N-acetyl-meta-aminophenol (AMAP) after four discrete hypotheses were tested to
ndpoint are shown below the symbols for each endpoint/hypothesis combination.
T), the differences were averaged.
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pecies) is several orders of magnitude lower than the amount of
otal reactive metabolite generated. Thus, the simulations may  be
ointing to a radical conclusion: covalent binding may  simply be a
orrelative observation associated with reactive metabolites, with
ittle to no mechanistic link to the actual cause of hepatocyte death.
nder this scenario, the reactive metabolite itself, when unbound
o proteins or GSH (particularly following depletion), is the direct
nitiator of oxidative stress via interactions with mitochondria. To
ate, the drug-induced liver injury literature has produced no direct
vidence to refute this point, yet many publications point to cova-
ent adducts as a causative feature of reactive metabolite-induced
njury (Davern et al., 2006; McGill et al., 2013; Pumford et al., 1990).
Hypothesis 3 contains one important omission: DILIsym® v1A
annot account for which proteins in the hepatocyte are bound
y an APAP reactive metabolite compared to an AMAP reactive
etabolite. Many researchers have postulated that selective pro-
ein binding accounts for the observed differences between the two
nalogues (Birge et al., 1989; Holme et al., 1991; Rashed et al., 1990;
oberts et al., 1990; Streeter et al., 1984; Tirmenstein and Nelson,
989). The theory proposes that the AMAP reactive metabolite is
ore reactive, which is well supported experimentally (Rashed
t al., 1990; Streeter et al., 1984), and thus binds to proteins closer
o the site of generation than the APAP reactive metabolite (NAPQI),
hich is able to diffuse to more critically important sites in the cell
nd initiate changes there. This theory is neither directly supported
or directly refuted by the simulation results shown herein. On the
ther hand, the modelling in Hypotheses 1 and 2 assumes that APAP
nd AMAP have equipotent reactive metabolites, accounts for the
ifferences in the magnitude of reactive metabolites produced, and
eads to results consistent with the literature. This indirect evidence
an be interpreted in the following way: selective binding to less
ritical proteins by the AMAP reactive metabolite may  be occurring,
ut it is not necessary to explain the differences in observed toxic-
ty. In other words, assuming equipotency and accounting for mass
ifferences are sufﬁcient steps to explain the results, so separat-
ng the selective binding theory from the results is difﬁcult unless
 mouse study can be done where equal amounts of total reac-
ive metabolites (from APAP and AMAP) are produced (not equal
mounts of protein adducts). Beyond the simulations, Holme et al.
tudied the in vitro potency of the reactive metabolites of APAP
nd AMAP and concluded that “. . .the relative toxic potencies of
he hydroquinone and quinone metabolites of AMAP were com-
arable to that of NAPQI.  . .”  (Holme et al., 1991). Direct in vitro
vidence suggests the two reactive metabolites have similar toxic
otencies on a equimolar basis. Lastly, Fig. 7 shows how small the
mount of covalent adducts produced is compared to other down-
tream metabolites recovered. If selective binding were a critical
river of the divergent response, it would have to be extremely
elective to have such a drastic effect with such a small amount of
roteins affected. Taken as a whole, these simulation results and
ublished data have led us to conclude that increased reactivity of
MAP reactive metabolites has little bearing on the toxicity (or lack
hereof) seen in mice.
Hypothesis 4 emphasized a potential difference in the equimolar
oxic potency of the APAP reactive metabolite compared to AMAP,
ith no regard for drug metabolism differences. This hypothe-
is disagrees with the data from Holme et al. (1991), suggesting
quipotency of the reactive metabolites. While this led to inac-
urate simulations for cumulative metabolite outputs and GSH
epletion, the simulations help to make a key point: focusing on
he downstream mechanisms of injury to elucidate a divergent
bserved response does not make sense unless the exact same
mount of reactive metabolite was produced in the mice for both
ompounds. Thus, this hypothesis was deemed less credible than
ypothesis 1 or 2. While concurrent differences in drug metabolism
nd reactive metabolite potency were not simulated, the sametters 226 (2014) 163–172
point made regarding Hypothesis 3 is relevant: the AMAP reactive
metabolite may  be causing less havoc in the cell on an equimolar
basis, but this is not necessary to explain the differences in observed
toxicity in the simulations. This points to downstream differences
as a minor player at best. Table 2 summarizes the results of compar-
ing simulations of various hypotheses with reported data. Overall,
the modelling supports a difference in the net quantity or cumula-
tive ﬂux of reactive metabolite as the most plausible explanation
for the differences in response between APAP and AMAP in mice.
At ﬁrst glance, this may  seem like an obvious conclusion. Nonethe-
less, the idea that simple mass-related (ﬂux) issues account for such
a well studied divergence in response, and not covalent adducts
or mechanistic divergences downstream of drug metabolism, has
rarely been suggested in a long history of APAP/AMAP research.
This highlights the point that quantitative, mechanistic modelling
tools provide the means to test theories that are otherwise difﬁcult
to test.
This exercise has supported a hypothesis that may  be refuted
or accepted in the future as others continue to study APAP and
AMAP. At the very least, it will help inform and motivate additional
thoughts and studies.
4.2. Limitations
In this example, DILIsym® v1A supported the amount of reac-
tive metabolite produced as the key differentiator between APAP
and AMAP in mice. Still, there are several general limitations of
the DILIsym® model and the mechanistic modelling approach that
must be taken into consideration alongside this conclusion. First,
simulation results must always be considered as one additional
piece of information rather than as the entirety of evidence for
or against a particular hypothesis or proposed mechanism. Math-
ematical modelling tools are designed to improve understanding
of dynamic systems, but they always include approximations that
limit their accuracy. Experimental results, experience, and many
other factors need to weigh heavily on conclusions regarding the
potential for DILI. Another signiﬁcant challenge for building and
using the DILIsym® model lies in data gaps in the DILI literature.
Certain aspects of the model, such as autoprotection (adaptation),
oxidative stress production from reactive metabolites, and selec-
tive protein binding are described as well as possible, but the model
presses the edge of the data frontier. This is both a limitation and
an exciting opportunity, as the model can be used to identify where
data gaps occur and guide new experimentation.
Additional limitations related directly to the assumptions made
for APAP and AMAP are also important to highlight. Throughout this
work, it was assumed that APAP and AMAP were identical with
regard to their effects, except for the speciﬁc delineations men-
tioned for Hypotheses 1–4. The hope is that this over-simpliﬁed
representation allowed for a better understanding of the critical
elements involved in causing DILI without excessive noise that
could potentially drown out primary conclusions. On the other
hand, such a simpliﬁcation could lead to omissions that make
the supported hypotheses less valid. Also, DILIsym® v1A lacks
a representation of the speciﬁc proteins conjugated to reactive
metabolites. The theory of selective binding cannot be directly
addressed with the model for this reason. Despite the contention
that such a small absolute amount of reactive metabolites produced
(Fig. 7) may  make the selective binding theory less plausible, it is
nonetheless an important possibility that was not tested.
Furthermore, one additional hypothesis that is missing from this
analysis includes selective depletion of GSH from the mitochon-
drial GSH pool (Tirmenstein and Nelson, 1990, 1989). A thorough
review of the literature has led the authors to put forth the follow-
ing premise: GSH is transported into hepatocellular mitochondria
through a one-way, inﬂux transport system (Fernández-Checa
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t al., 1997; Lu, 1999; Lu et al., 1992; Shan et al., 1993; Zhong
t al., 2008). This avoids depletion of mitochondrial GSH until
he cytosolic GSH is sufﬁciently depleted to prevent further GSH
nﬂux into the mitochondria (and the mitochondrial GSH has been
xhausted). Under this premise, GSH depletion within mitochon-
ria for APAP (but not AMAP) would simply be the result of more
verall cytosolic GSH depletion in the APAP case, as opposed to evi-
ence for a selective mechanism of mitochondrial GSH depletion by
he APAP reactive metabolite when compared to the AMAP reac-
ive metabolite. This is not true for cases of ethanol administration,
here the mitochondrial GSH inﬂux system is selectively inhibited
Fernández-Checa et al., 1997; Tavoloni and Berk, 1993). Therefore,
itochondrial GSH depletion was not included as an alternative
ypothesis. Technically, this hypothesis would fall under Hypothe-
es 1 and 2, since production of more reactive metabolites would
ead to lower cytosolic GSH concentrations. Lower cytosolic GSH
ould eventually lead to mitochondrial GSH depletion. While the
ationale behind omitting selective GSH depletion as a stand-alone
ypothesis was based on literature, additional less understood
spects of this mechanism could be important, and were not con-
idered hererin.
Finally, Hypotheses 1–4 were considered in isolation within this
ork. While it is the authors’ opinions that they are probably not
ynergistic, making this approach valid, such synergies can rarely
e completely ruled out within the biological realm. Still, a lack
f representation of potential synergies within this work clearly
imits the ability for the conclusions to be interpreted as absolutely
eﬁnitive.
.3. Summary and conclusions
A mechanistic, mathematical model (DILIsym® v1A) of drug-
nduced liver injury predicted that the amount of reactive
etabolite produced from APAP or AMAP was the key differentia-
or for the degree of liver injury observed in mice, with signiﬁcantly
ess reactive metabolite produced per mole of AMAP leading to
ess oxidative stress and injury. Within the simulations, this was
qually likely to have occurred from different afﬁnities for the rel-
vant enzymes responsible for drug metabolism or from direct CYP
nhibition by the AMAP reactive metabolite. The rate of reactive
etabolite binding to proteins and differences in downstream (tox-
codynamic) processes were not predicted to be as plausible. This
roposed explanation for the divergence in response between the
wo isomers in mice will hopefully spur additional, conﬁrmatory
tudies in the future.
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